• BV6 and IAP Antagonism: Redefining Experimental Cell Death M

  2026-07-17

  Explore how BV6, a selective IAP antagonist, enables advanced apoptosis induction in cancer and endometriosis models. This article delivers a uniquely nuanced analysis of programmed cell death pathways and practical assay design, setting it apart from prior protocol-driven content.

• Atrial Natriuretic Peptide: Mechanisms & Translation in Card

  2026-07-17

  This thought-leadership article examines the mechanistic actions of Atrial Natriuretic Peptide (ANP) in cardiovascular homeostasis and its strategic application in translational research. By bridging biochemical pathways with experimental and clinical priorities, it provides actionable guidance for researchers using high-purity ANP, such as APExBIO’s rat ANP peptide, while extending the discussion beyond standard product summaries.

• CD40 and STING Competition Drives B Cell Activation in ESCC

  2026-07-16

  This study reveals how CD40 and STING competitively bind TRAF2 to regulate IRF4-mediated B cell activation within tertiary lymphoid structures in esophageal squamous cell carcinoma (ESCC). The findings clarify the molecular basis for TLS-driven antitumor immunity and suggest avenues for biomarker and therapeutic development.

• RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy & C

  2026-07-16

  RapaLink-1 enables precise, robust mTOR pathway inhibition for both cancer and embryonic dormancy research. Its dual-pocket binding overcomes resistance mutations, offering superior potency and reproducibility in advanced cell and animal models.

• CCCP and Mitochondrial Morphology: Advanced Assays for Neuro

  2026-07-15

  Explore how CCCP (carbonyl cyanide m-chlorophenyl hydrazine) enables precise disruption of mitochondrial proton gradients to power advanced, AI-driven analyses of mitochondrial morphology in neurodegeneration research. This article delivers expert insights beyond basic workflows—bridging molecular uncoupling to next-gen biomarker discovery.

• Topological Stress Drives Persistent rDNA Lesions via PML-Nu

  2026-07-15

  This study reveals how topological stress and RNA polymerase I inhibition induce persistent DNA lesions in ribosomal DNA, triggering the formation of PML-nucleolar associations (PNAs). These findings clarify the cellular mechanisms linking rDNA instability, DNA repair pathway choice, and senescence, with significance for cancer and genome stability research.

• Standardized Whole-Blood Stimulation Reveals Immune-Metaboli

  2026-07-14

  This study introduces a robust protocol for analyzing immune responses via standardized whole-blood stimulation with metabolic modulation. By systematically evaluating how metabolic inhibitors influence cytokine production, the work provides a crucial methodological advance for immunometabolism and translational immuno-oncology research.

• Cepharanthine in Apoptosis Research: Protocols and Use-Cases

  2026-07-14

  Cepharanthine, a biscoclaurine alkaloid, is redefining apoptosis and endometriosis research by bridging robust in vitro organoid assays and in vivo models. This guide offers practical workflows, optimization insights, and new evidence for leveraging Cepharanthine in disease modeling and anticancer therapy studies.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Size: New Ins

  2026-07-13

  The referenced study demonstrates that selective pharmacologic inhibition of SPP1 in tumor-associated macrophages (TAMs) leads to significant tumor regression in murine models, establishing SPP1 as a tractable and direct therapeutic target. This work introduces a phenotype-based screening and nanoformulation approach, providing a new framework for targeting immunosuppressive myeloid cells in the tumor microenvironment.

• PPARγ Activation Modulates Macrophage Polarization to Attenu

  2026-07-13

  This study demonstrates that activation of PPARγ, including by pioglitazone, regulates the balance between pro-inflammatory (M1) and anti-inflammatory (M2) macrophages via STAT-1/STAT-6 pathways, significantly reducing disease severity in a mouse model of inflammatory bowel disease. The mechanistic insights offer new directions for immune modulation in IBD and related inflammatory disorders.

• PPARγ Activation Shifts Macrophage Polarization in IBD via S

  2026-07-12

  This study demonstrates that activating PPARγ, including with pioglitazone, regulates macrophage polarization—suppressing pro-inflammatory M1 and promoting anti-inflammatory M2 phenotypes—through STAT-1/STAT-6 signaling, effectively attenuating DSS-induced inflammatory bowel disease in mice. These findings provide mechanistic insight relevant for translational research on immune modulation in chronic intestinal inflammation.

• Mutational Profiling of Myeloma Cell Lines: Implications for

  2026-07-10

  This comprehensive exome-wide analysis of 30 human multiple myeloma cell lines reveals key mutational drivers and pathway alterations underlying tumor progression and therapy resistance. The study provides a high-resolution genetic resource, enabling more precise model selection and experimental design for hematological malignancy research.

• Gene Expression Predicts Olaparib Response in Mesothelioma M

  2026-07-09

  Borchert et al. (2019) demonstrated that gene expression profiling of homologous recombination repair (HRR) pathway components can identify malignant pleural mesothelioma (MPM) subgroups with heightened susceptibility to Olaparib (AZD2281). Their findings suggest that BAP1-mutated and BRCAness-positive tumors may benefit from PARP inhibition, paving the way for more targeted cancer therapy strategies in MPM.

• Universal HPLC Method for Dual-Loaded Liposome Encapsulation

  2026-07-09

  This study introduces a nanoparticle exclusion HPLC method enabling accurate, simultaneous measurement of encapsulation efficiency for hydrophilic and lipophilic drugs in dual-loaded liposomes. The approach is validated across multiple drug pairs—including oleanolic acid—addressing a major analytical challenge in advanced drug delivery research.

• Microfluidic Size Control of LNPs Enhances mRNA Delivery Eff

  2026-07-08

  Kim et al. present a simulation-guided microfluidic approach for precise control of lipid nanoparticle (LNP) size, demonstrating that smaller LNPs markedly improve mRNA transfection both in vitro and in vivo. These findings emphasize the critical role of nanoparticle size in optimizing mRNA delivery systems, informing the rational design of therapeutics.

8364 records 5/558 page Previous Next 12345 下5页 Last page